Explore

Trendline Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Trendline Trendline
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials
Trendline Trendline
DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements
Trendline Trendline
Quantum-Si Reports Q1 2026 Financial Results and Advances Proteus Development

Quantum-Si Reports Q1 2026 Financial Results and Advances Proteus Development

Quantum-Si Reports Q1 2026 Financial Results and Advances Proteus Development
Trendline Trendline
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
Pfizer Maintains 2026 Guidance Amid Patent Expiration Challenges

Pfizer Maintains 2026 Guidance Amid Patent Expiration Challenges

Pfizer Maintains 2026 Guidance Amid Patent Expiration Challenges